大血管闭塞单独血管内取栓:基于Meta分析的成本效果评价
从荷兰医疗支付方视角,用Markov模型模拟15年随访,比较直接取栓与取栓前静脉阿替普酶的成本效果;基于6项随机对照试验的功能结局,取栓前静脉阿替普酶每例增加0.05质量调整生命年、多花2817美元,增量成本效果比为62287美元;在52500美元阈值下不具成本效果,在84000美元阈值下可能具成本效果。
要点
- 取栓前静脉阿替普酶较单独取栓每例增加0.05质量调整生命年,增量成本2817美元,增量成本效果比62287美元。
- 概率分析示取栓前静脉阿替普酶在52500美元和84000美元阈值下具成本效果的概率分别为45%和54%。
- 基于不同试验人群的功能结局,取栓前静脉阿替普酶的成本效果结论可变。
核心结论
- 在荷兰,大血管闭塞患者取栓前静脉阿替普酶在52500美元阈值下不具成本效果,但在84000美元阈值下可能具成本效果。
- 基于不同试验人群的3个月功能结局差异影响取栓前静脉阿替普酶的成本效果。
研究设计与样本
- 决策分析采用Markov模型模拟15年随访,从荷兰医疗支付方视角估算总成本、质量调整生命年和增量成本效果比。
- 假设队列为10000例年龄70岁的大血管闭塞患者,行蒙特卡洛模拟。
- 每种治疗的功能结局取自6项随机对照试验的汇总结果。
主要发现
- 基于6项随机对照试验意向性治疗人群的功能结局,取栓前静脉阿替普酶较单独取栓每例增加0.05质量调整生命年,增量成本2817美元,增量成本效果比62287美元。
- 概率分析示取栓前静脉阿替普酶在52500美元和84000美元阈值下具成本效果的概率分别为45%和54%。
- 采用6项随机对照试验的事后改良按治疗分析功能结局(情景1)时,取栓前静脉阿替普酶在52500美元阈值下64%的模拟中具成本效果,在84000美元阈值下79%的模拟中具成本效果。
- 采用欧洲随机对照试验(情景2)时,取栓前静脉阿替普酶在52500美元阈值下81%的模拟中具成本效果,在84000美元阈值下91%的模拟中具成本效果。
- 采用一项荷兰随机对照试验(情景3)时,取栓前静脉阿替普酶在52500美元阈值下50%的模拟中具成本效果,在84000美元阈值下67%的模拟中具成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of intravenous thrombolysis with alteplase before endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion remains debated. In this study, we analyzed the cost-effectiveness of EVT alone versus intravenous alteplase before EVT in patients directly admitted to EVT-capable stroke centers from the Dutch health care payer perspective. METHODS: A decision analysis was performed using a Markov model with 15-year simulated follow-up to estimate total costs, quality-adjusted life years, and an incremental cost-effectiveness ratio of intravenous alteplase before EVT compared with EVT alone. A hypothetical cohort of 10 000 patients with large vessel occlusion aged 70 years was run in Monte Carlo simulation. Functional outcome of each treatment was derived from pooled results of 6 randomized controlled trials (RCTs). Uncertainty was assessed by probabilistic analyses, scenario analyses, and 1-way sensitivity analyses. RESULTS: Using functional outcomes obtained from 6 RCTs (intention-to-treat population), intravenous alteplase before EVT resulted in 0.05 quality-adjusted life years gained at an additional $2817 compared with EVT alone, resulting in the incremental cost-effectiveness ratio of $62 287. Probabilistic analyses showed that intravenous alteplase before EVT had a probability of 45% and 54%, respectively, of being cost-effective at the $52 500 and $84 000 thresholds. Restricting functional outcomes from our post hoc modified as-treated analysis of 6 RCTs (scenario 1), European RCTs (scenario 2), or a Dutch RCT (scenario 3), intravenous alteplase before EVT was cost-effective in 64%, 81%, and 50% of simulations at the $52 500 threshold, and 79%, 91%, and 67% of simulations at the $84 000 threshold. CONCLUSIONS: Intravenous alteplase before EVT was not cost-effective in patients with large vessel occlusion in the Netherlands at the $52 500 threshold but possibly cost-effective at the $84 000 threshold. Variable functional outcomes at 3 months based on different trial populations affected the cost-effectiveness of intravenous alteplase before EVT.
引用
- Nguyen CP, Lahr MMH, van der Zee DJ, et al. Endovascular Thrombectomy Alone for Large Vessel Occlusion: A Cost-Effectiveness Evaluation Based on Meta-Analyses. Stroke. 2024. PMID: 39129622. doi:10.1161/STROKEAHA.124.047276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。